TEVA
$30.09
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Recent News
Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now?
Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $31.52 as of March 10th. TEVA’s trailing and forward P/E were 26.03 and 11.60 respectively […]
Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its 75% One Year Rally?
If you are wondering whether Teva Pharmaceutical Industries still represents good value after a strong run, or if you may be late to the story, this article focuses on what is currently reflected in the share price. The stock closed at US$28.57, with a 1 year return of 75.0% and a 3 year return of 241.7%, even though the last 7 days and 30 days show declines of 8.0% and 15.9% respectively. Recent attention on Teva has centred on its role in the generic and specialty drug space and ongoing...
Does Blackstone’s Private Credit Strains And AI Push With Anthropic Reshape The Bull Case For BX?
In recent days, Blackstone has been at the center of sector-wide turbulence in private credit after JPMorgan Chase moved to restrict lending to private credit providers, while the firm also advanced deals ranging from a majority stake in Advanced Cooling Technologies to a US$400 million life sciences funding agreement with Teva Pharmaceuticals. At the same time, Blackstone is exploring an AI joint venture with Anthropic to deploy Claude across portfolio companies and has strengthened its...
A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Share Price Pullback
What recent performance says about Teva Pharmaceutical Industries (TEVA) Teva Pharmaceutical Industries (TEVA) has caught investor attention after a mixed run, with a 2.5% decline over the past day and an 8% pullback over the past week tempering earlier gains. See our latest analysis for Teva Pharmaceutical Industries. While the recent 1-day, 7-day and 30-day share price returns show weakness, the latest price of $28.57 sits against a very strong 1-year total shareholder return of 74.95%,...
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics
Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Da